Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12439801 | 0.89 | SYK (0.41) | SYKALDH1A1L3MBTL1MAPK1POLB | |
| SCHEMBL8046788 | 0.83 | SYK (0.39) | SYKAKT1ALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL14439276 | 0.83 | SYK (0.39) | SYKAKT1ALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL2137495 | 0.81 | SYK (0.46) | SYKALDH1A1L3MBTL1MAPK1POLB | |
| SCHEMBL2138671 | 0.81 | SYK (0.46) | SYKALDH1A1L3MBTL1MAPK1POLB | |
| SCHEMBL2139397 | 0.79 | SYK (0.42) | SYKALDH1A1L3MBTL1MAPK1POLB | |
| SCHEMBL2139616 | 0.79 | SYK (0.42) | SYKALDH1A1L3MBTL1MAPK1POLB | |
| SCHEMBL14768484 | 0.79 | ALDH1A1 (0.43) | SYKALDH1A1L3MBTL1MAPK1SMN1; SMN2 | |
| SCHEMBL25250386 | 0.78 | ALDH1A1 (0.41) | SYKALDH1A1L3MBTL1MAPK1POLB | |
| SCHEMBL29415387 | 0.78 | ALDH1A1 (0.41) | SYKALDH1A1L3MBTL1MAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153100-B2 | Methods and compositions for F-18 labeling of proteins, peptides and other molecules | IMMUNOMEDICS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090246130-A1 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090246130-A1 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules | F13B, TFRC, F13A1 | SYK 2086/4885AKT1 4190/4885ALDH1A1 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.